Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric B Haura

Showing results (161-170 of 201) with videos related to

Pageof 21
Sort By:
Oncotargets and Therapy|September 19, 2017
Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumorsBen C Creelan, Dmitry I Gabrilovich, Jhanelle E Gray, et al.
Molecular Systems Biology|November 6, 2013
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanismsJiannong Li, Keiryn Bennett, Alexey Stukalov, et al.
Science Signaling|August 16, 2022
IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cellsLily L Remsing Rix, Natalia J Sumi, Qianqian Hu, et al.
Cancer Immunology, Immunotherapy : CII|September 14, 2018
A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinomaJhanelle E Gray, Alberto Chiappori, Charlie C Williams, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2023
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS studyKeunchil Park, Joshua K Sabari, Eric B Haura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2022
Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung CancerAlberto A Chiappori, Ben Creelan, Tawee Tanvetyanon, et al.
Nature Communications|December 7, 2016
MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutatedMichal Smida, Ferran Fece de la Cruz, Claudia Kerzendorfer, et al.
Patient Education and Counseling|December 3, 2017
Patient, caregiver and physician perspectives on participating in a thoracic rapid tissue donation programGwendolyn P Quinn, Rebecca D Pentz, Teresita Muñoz-Antonia, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 9, 2024
Rapid Autopsy to Define Dendritic Cell Spatial Distribution and T Cell Association in Lung AdenocarcinomaHilal Ozakinci, Xiaofei Song, Gina S Nazario, et al.
Molecular Cancer Research : MCR|January 13, 2022
Integrated Proteomics-Based Physical and Functional Mapping of AXL Kinase Signaling Pathways and Inhibitors Define Its Role in Cell MigrationAnurima Majumder, Sina Hosseinian, Mia Stroud, et al.
Pageof 21

Showing results (161-170 of 201) with videos related to

Sort By:
Pageof 21
Oncotargets and Therapy|September 19, 2017
Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumorsBen C Creelan, Dmitry I Gabrilovich, Jhanelle E Gray, et al.
Molecular Systems Biology|November 6, 2013
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanismsJiannong Li, Keiryn Bennett, Alexey Stukalov, et al.
Science Signaling|August 16, 2022
IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cellsLily L Remsing Rix, Natalia J Sumi, Qianqian Hu, et al.
Cancer Immunology, Immunotherapy : CII|September 14, 2018
A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinomaJhanelle E Gray, Alberto Chiappori, Charlie C Williams, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2023
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS studyKeunchil Park, Joshua K Sabari, Eric B Haura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2022
Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung CancerAlberto A Chiappori, Ben Creelan, Tawee Tanvetyanon, et al.
Nature Communications|December 7, 2016
MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutatedMichal Smida, Ferran Fece de la Cruz, Claudia Kerzendorfer, et al.
Patient Education and Counseling|December 3, 2017
Patient, caregiver and physician perspectives on participating in a thoracic rapid tissue donation programGwendolyn P Quinn, Rebecca D Pentz, Teresita Muñoz-Antonia, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 9, 2024
Rapid Autopsy to Define Dendritic Cell Spatial Distribution and T Cell Association in Lung AdenocarcinomaHilal Ozakinci, Xiaofei Song, Gina S Nazario, et al.
Molecular Cancer Research : MCR|January 13, 2022
Integrated Proteomics-Based Physical and Functional Mapping of AXL Kinase Signaling Pathways and Inhibitors Define Its Role in Cell MigrationAnurima Majumder, Sina Hosseinian, Mia Stroud, et al.
Pageof 21